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invoked for the USA and EU), no nation 
had legislation requiring the pharma-
ceutical industry (which is often the 
ﬁ rst to know) to inform the relevant 
medicines regulatory authority (MRA) 
of drug falsiﬁ cation. It is extraordinary 
that, in 2014, such systems are widely 
in place for suspicious aircraft parts but 
not for suspicious medicines.8 WHO’s 
new Rapid Alert System facilitates 
information sharing on poor-quality 
medicines between medicines 
regulatory authorities (MRAs).5 It 
should be mandatory and included in 
the International Health Regulations.1 
When pharma ceutical companies 
and others encounter suspicious 
medicines or medical products, there 
remains tension between commercial 
interests, the need to investigate, 
and the requirement to act quickly to 
safeguard public health. There is no 
consensus mechanism to adjudicate 
these decisions from a public health 
perspective. This stagnant system 
must change. All reports of suspect 
medicines known to the pharma-
ceutical industry and others should 
be reported to the WHO and MRA 
within 1 week for investigation, risk 
assessment, and appropriate dis-
semination. If those reporting wish 
delayed onward dissemination, an 
advisory committee of MRAs and 
WHO with independent advice should 
perform a rapid public health risk 
assessment. Compliance should be 
reported through a mechanism such as 
the Access to Medicine Index.
Falsiﬁ ed medicines in 
Africa: all talk, no action
 Poor-quality medicines and medical 
products, both substandard and 
falsified, cause avoidable morbidity, 
mortality, drug resistance, and loss 
of faith in health systems, especially 
in low-income and middle-income 
countries.1–3 We report the analysis of 
two falsiﬁ ed medicines from Angola 
and discuss what lessons such a 
discovery could hold.
The tablets were seized at Luanda 
docks in June, 2012, after failing 
Minilab testing.4,5 The seized shipment 
was enormous (1·4 million packets), 
and hidden in loudspeakers in a 
container from China.4 One sample 
was labelled as an adult course of the 
vital antimalarial drug artemether-
lumefantrine, and as being manu-
factured by “Novartis Pharma ceutical 
Corpor ation”; it also bore an Aﬀ ordable 
Medicines Facility—malaria logo 
(ﬁ gure). Another sample was labelled 
as the broad-spectrum anthelmintic 
mebend azole,  and as being 
manufactured by “Janssen-Cilag SpA”.
We analysed the tablets with an 
array of analytical platforms, including 
high-performance liquid chromato-
graphy, ambient ionisation mass 
spectrometry, Raman spectroscopy, 
Xray powder diﬀ raction (XRD) analysis, 
nuclear magnetic resonance spectroscopy, 
isotope-ratio mass spectrometry (IRMS), 
and botanical assays. Packaging was 
analysed with the portable counterfeit 
detection device CD-3 (see appendix 
for detailed methods).
No artemether, lumefantrine, 
or other active pharmaceutical 
ingredients were detected in the 
“artemether-lumefantrine” tablets by 
any of the chemical assay techniques. 
Brushite and three different yellow 
dyes (pigment yellow 3, pigment 
yellow 81, and pigment yellow 151) 
were detected. No mebendazole was 
detected in the “mebendazole” tablets, 
but the active ingredient levamisole 
(270 mg/tablet) was. XRD analysis 
revealed the presence of calcite 
(CaCO3), with IRMS data suggesting 
that it was either hydrothermal or 
medical in origin. The CD-3 ultraviolet-
visible and infrared images of the 
falsified and genuine packaging 
readily showed substantial diﬀ erences 
between them. Language errors on 
the “mebendazole” packages were 
common, suggesting that the forger 
may have had some knowledge of 
English but little of French and Spanish.
Falsified artemether-lumefantrine 
has also been described across central 
and west Africa.5 Such products will 
inevitably cause increased morbidity, 
mortality, and transmission, and 
could falsely indicate that artemisinin 
resistance had arrived. Additionally, 
modelling strongly suggests that under-
dosing is an important contributor 
to resistance.6 Therefore, if patients 
consume co-circulating falsified and 
substandard medicines sequentially, so 
that heavy parasite burdens encounter 
low drug concentrations, the risks of 
engendering resistance are high.
The presence of the anthelmintic 
levamisole is also worrying because 
it has been withdrawn from many 
markets for human use owing to its 
association with agranulocytosis. The 
recent epidemic of necrotising vasculitis 
resulting from “cutting” cocaine with 
levamisole7 suggests links between 
criminals who produce narcotics and 
those who produce falsiﬁ ed medicines.
These examples illustrate the major 
obstacles to improving the global 
medicine supply. First, there is no global 
system for the mandatory reporting, 
assessment, and dis semination of 
information on suspicious medicines. 
The seizure in Angola was ﬁ rst brought 
to public attention on Facebook after 
5 months, and in the printed press after 
11 months.4 It was Facebook who ﬁ rst 
alerted those responsible for malaria 
control liaison at WHO. Although 
such reporting is commendable, it is 
grossly inadequate for tropical public 
health what proportion of African 
malaria patients and their families 
reads Facebook and the Wall Street 
Journal? Until 2011–12 (when it was 
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7% of sub-Saharan countries had a 
“moderately functioning MRA”.10 We 
cannot expect the world’s medicine 
supply to improve without co ordinated 
functional MRAs. They are essential 
for the interventions needed, and to 
ensure that the beneﬁ ts of increased 
accessibility to free or inexpensive 
internationally ﬁ nanced medicines and 
inexpensive generics are translated 
eﬀ ectively into improved public health. 
The Access to Medicines movement 
has been very important in improving 
access to essential medicines; however, 
much more emphasis is needed now 
on access to good quality medicines.
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Second, recent inaction regarding 
medicine quality has involved disputes 
over definitions from a trade and 
political perspective. These disputes 
must have damaged public health. The 
acronym NATO (no action—talk only), 
sadly reﬂ ects recent history. Extended 
discussion at World Health Assemblies 
culminated in 2011 with the formation 
of a Member State mechanism. 
However, chairmanship disagreements 
then apparently delayed discussion 
for 6 months.9 The group now has 
meetings just once per year. 
The terminology remains confused—
for example, a recent US Institute of 
Medicine report on medicine quality2 
did not state clearly what term should 
be used for medicines that are poor 
quality but not falsiﬁ ed. Here we have 
used the distinction between falsiﬁ ed 
(or counterfeit or spurious medicines—
ie, those deliberately and fraudulently 
mislabelled with respect to identity or 
source) and substandard medicines 
(ie, genuine medicines produced by 
authorised manufacturers that do 
not meet quality speciﬁ cations set for 
them by national standards).3 To avoid 
any intellectual property connotations, 
the term falsiﬁ ed is used here instead 
of counterfeit.3 We believe that this is 
the clearest way forward.
Third, the extradition and pros-
ecution of criminals, such as those 
trading in falsiﬁ ed medicines between 
China and Angola, is extremely 
difficult as falsification of medicine 
or medical products is not an inter-
national crime, and definitions and 
laws are inconsistent. An international 
public health convention could assist 
in combating criminal networks and 
provide a ﬁ nancing mechanism for MRA 
and factory support (ie, detecting and 
reducing factory errors or negligence).3 
The Insitute of Medicine favours soft-
law solutions,2 but the lack of legally 
binding force would neuter action.
Fourth, the enormous investment 
in accessible medicines and medical 
products without investment in 
checking their quality is profoundly 
illogical. WHO estimates that only 
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Standards of mebendazole (CAS Number 31431-39-7; EC Number 250-635-4) and 
levamisole (CAS-No. 16595-80-5; EC-No.240-654-6, Vetranal-analytical grade) 
were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA) in their powder 
form. 
 
High Performance Liquid Chromatography 
 
The ‘artemether-lumefantrine’ was analysed by High Performance Liquid 
Chromatography with Diode Array Detection (HPLC-DAD) (Agilent 1100, Agilent 
Technologies, Palo Alto, CA, USA). Ao-2012-1 was not analysed by HPLC-DAD 
due to limited sample availability. High performance liquid chromatography with 
diode array detection (HPLC-DAD). Two Ao-2012-2 tablets were analyzed by high 
performance liquid chromatography with diode array detection (Agilent 1100 
Series, Agilent Technologies, Inc., Palo Alto, CA, USA) for artemether and 
lumefantrine. The entire tablet was weighed, pulverized, dissolved in 
methanol/acetic acid (9:1 v/v) and filtered through a 0.45 µm membrane. The 
	   2	  
sample extract was injected directly into the HPLC system with UV detection 
wavelength set at 210 nm for artemether and lumefantrine. Component separation 
was achieved using a 150 x 4.6 mm C18, 5 µm column (Supelco Analytical, 
Bellefonte, PA, USA) with a mobile phase consisting of 65% ACN and 35% 0.05M 
sodium perchlorate (pH 2.5) and flow rate of 1 mL min-1. The lower limits of 
detection under these conditions were equivalent to a tablet containing 2 mg of 
artemether and 0.05 mg of lumefantrine. Authentic tablets were also analyzed as a 
positive control. 
 
Sample preparation for Mass Spectrometry 
For analysis of the Ao-2012-1 suspect tablet, 0.08 g of the tablet was dissolved in 
10 mL of solvent (80:20 v/v solution of methanol and water with 1% acetic acid). 
After vortex mixing for 3 minutes followed by sonication for 30 minutes, 2 µL of 
the supernatant was diluted to 300 µL using the solvent. Mass spectrometric 
analysis was performed with this sample solution. Standards of mebendazole and 
levamisole were also prepared in methanol-water solvent. For quantitation of 
levamisole, a 6.57 mM stock solution of the levamisole standard was used to 
prepare standards ranging between 4.4 µM and 440 µM. For analysis of the Ao-
2012-2 suspect tablet, 75.8 mg of the tablet was dissolved in 10 mL of solvent 
(80:20 v/v solution of methanol and water with 1% acetic acid) and protocols 
identical to those for Ao-2012-1 were followed. 
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Mass Spectrometry 
Mass spectrometry (MS) techniques were used to determine the chemical composition 
of sample Ao-2012-1. The MS platforms used for MS analysis were: 1) Direct 
analysis in real time-mass spectrometry (DART-MS), 2) DART-tandem MS (DART-
MS/MS), 3) ultra-high performance liquid chromatography MS (UHPLC-MS), and 4) 
UHPLC-MS with travelling wave ion mobility spectrometry separation (UHPLC-
TWIMS-MS) (Harris et al. 2008, Monge et al. 2013). DART-MS allows rapid 
analysis of solid samples under ambient conditions with minimal or no sample 
preparation for the determination of chemicals present in the sample. In DART with 
tandem MS (DART-MS/MS), detected ions are fragmented to produce product ions 
and the fragmentation pattern thus obtained aids in the identification and verification 
of the chemicals detected. Introduction of UHPLC separation prior to MS analysis, in 
addition to de-convoluting the mass spectrum in a second dimension by separating the 
chemicals present in a mixture solution, provides a secondary parameter (retention 
time), for compound identity verification. Further introduction of TWIMS separations 
in the UHPLC-MS platform provides an additional analytical parameter (drift time) 
for compound identity verification, in addition to separating the chemicals in the third 
dimension prior to analysis by mass spectrometry. Thus, utilizing these platforms a 
chemical can be identified and its identity validated using five parameters specific to 
the chemical of interest. These parameters are 1) mass-to-charge ratio of the analyte 
ion along with its specific adduct or cluster ions, 2) isotopic distribution matching, 3) 
fragmentation pattern, 4) retention time, and 5) drift time.  
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For DART-MS and DART-MS/MS analysis, a commercial DART-100 ion source 
(IonSense, Saugus, MA, USA) was coupled in-line through a VAPUR interface 
(IonSense, Saugus, MA, USA) with a Bruker micrOTOF-Q I mass spectrometer 
(Bremen, Germany). Detailed description of the DART-100 ion source is available 
elsewhere (Cody et al. 2005, Cody et al. 2005). The DART working gas (high purity 
He, 99.995% Airgas, Atlanta, GA) was supplied to the ion source at a flow rate of 1 L 
min-1 and was heated to 250 oC. The DART ion source and the mass spectrometer 
voltage settings were optimized for maximum ion transmission in the m/z range of 50-
1200. The mass spectrometer was mass calibrated using a 10 µM methanol solution of 
PEG 400, PEG 600, and PEG 1000 calibration standards. The mass spectrometer 
provided a mass resolution of ~12,000 at m/z 393.2095 and ~9,000 at m/z 151.0964, 
and a typical mass accuracy of 2-5 ppm was obtained for acetaminophen as test 
compound. Experiments were performed in both positive and negative ion detection 
mode. For analysis of tablets, the coating was scratched with a razor blade, a few 
tablet particles were obtained by scratching the inside and outside surfaces of the 
tablet, the particles were placed on a Kimwipe, and deposited on the tip of a glass 
capillary by rubbing it against the Kimwipe. The capillary tip with the deposited 
sample was then introduced in front of the plasma plume exiting the DART source for 
sample ionization and subsequent detection by mass spectrometry. Powders of 
chemical standards were deposited on the capillary tip and analysed under identical 
experimental and instrumental conditions as those used for tablet analysis. The Bruker 
Daltonics DataAnalysis Version 4.0 software package was used for processing of all 
acquired data. Presence and identity of active pharmaceutical ingredients (APIs) and 
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excipients in the sample tablet was established by matching m/z values measured by 
the mass spectrometer with calculated exact m/z values, and values measured for the 
API standards, together with the isotopic abundances, and adduct, or fragment ions. 
For UHPLC-MS and UHPLC-TWIMS-MS analysis a Waters ACQUITY Ultra 
Performance LC (Waters Corporation, Manchester, UK) system, coupled to a Synapt 
G2 High Definition Mass Spectrometry system (Waters Corporation, Manchester, 
UK), which is a hybrid quadrupole-ion mobility-orthogonal acceleration time-of-flight 
instrument (Benton et al. 2012, Giles et al. 2004, Pringle et al. 2007) was used. The 
UHPLC system was fitted with a Waters ACQUITY UHPLC BEH C18 column (1.0 × 
100 mm, 1.7 µm particle size). The traveling wave ion mobility spectrometry 
(TWIMS) separation mode of the Synapt system was activated and optimized for 
UHPLC-TWIMS-MS analysis. All analyses were performed in the positive ion 
detection mode of the instrument. The mass spectrometer was calibrated across the 
50-1200 m/z range using a 0.5 mM sodium formate solution prepared in 90:10 2-
propanol:water v/v. Data were mass corrected during acquisition using a leucine 
enkephalin reference spray (LockSpray) infused at 2 µL min-1. Data acquisition and 
processing was carried out using Mass Lynx v4.1 and Drift Scope v2.1 (Waters Corp.). 
Chromatographic separation was achieved using acetonitrile (ACN) and water with 
1% acetic acid as mobile phase solvents and gradient elution with 10% ACN to 100% 
ACN in 4 minutes.  During the total run time of 6 minutes, mobile phase composition 
was 100% ACN between minute 4 and 5 and was reverted back to 10% ACN at 5.4 
minutes. The mobile phase flow rate was 0.3 mL min-1, the column temperature was 
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45°C, the autosampler tray temperature was set to 5°C, and the injection volume was 
5 µL.  
X-ray diffraction analysis 
X-ray powder diffraction (XRD) analysis based on diffraction peak angles and 
corresponding intensities can be employed to identify bulk unknown excipients. 
Experimentally-obtained XRD scans can be searched on powder diffraction files 
(PDF) databases to identify the unknowns in the sample. The powder diffraction files 
database is a collection of d-I data—the d-spacing (d) determined from the angle of 
diffraction and the intensity (I), experimentally measured for a phase-pure material. 
These data provide a “fingerprint” of the compound because the d-spacings are fixed 
by the geometry of the crystal and the intensities are dependent on the elements and 
their arrangement in the crystal structure. Thus, the d-I data can be used for 
identification of unknown materials by locating matching d-I data in the PDF with the 
d-Is obtained from the unknown. Experiments were run using a PANalytical XRD – 
Alpha-1 instrument with X’pert data acquisition program. The instrument emits Kα1 
radiation with a Cu source. Experimental parameters included a scan time of 40 
minutes with step size of 0.02 degrees. The beam width was restricted to 15 mm by 
use of a mask. Soller slit packs of 0.04 rad were used in the pre-diffraction and post-
diffraction optics with ½ anti-scatter slit and 5 mm receiving slit. The acquired scan 
was analyzed using PDF-4+ and High score plus software supported by the d-I 
database. 
MS pigment analysis 
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UHPLC-MS was also used to investigate the presence of pigments in sample Ao-
2012-2. For that purpose, 0.05 g of pulverized sample was dissolved in 2 mL of 
tetrahydrofurane. Then, the solution was sonicated for 30 minutes, and centrifuged at 
13,000 rpm for 20 minutes. UHPLC-MS analysis was performed in the negative ion 
mode. Chromatographic separation was achieved in 10 minutes using ACN and water 
with 1% acetic acid as mobile phase solvents and gradient elution with 5% ACN to 
95% ACN in 8 minutes, which was reverted back to 5% ACN at 9 minutes. The 
mobile phase flow rate was 0.3 mL min-1, the column temperature was 50°C, the 
autosampler tray temperature was set to 5°C, and the injection volume was 10 µL. 
IRMS 
Isotopic mass measurements were made using a Finnigan MAT253 IRMS mass 
spectrometer with Kiel carbonate preparation device.  Values were calibrated using 
NBS-19 and NBS-18, and internal precision met or exceeded 0.08‰ (1 sigma or 1 
standard deviation of replicate analyses of NBS-19 or of other in house standards). 
NMR analysis 
NMR experiments were performed at a temperature of 298 K on a Bruker-Biospin 
Avance II 500 NMR spectrometer, operated at a 1H frequency of 500 MHz. The 
instrument was equipped with a 5 mm 1H/X-broadband probe with gradient in the z-
direction. Acquisition parameters for the 1D 1H NMR experiments comprised 1H 
excitation with a 30 degree pulse followed by an acquisition of 65536 data points 
during a time of 3.17 s; and followed by a recycle delay of 1 s. A total of 16 scans 
were accumulated. Data were referenced with respect to the solvent peak of the 
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deuterated dimethyl sulfoxide (DMSO) at 2.5 ppm. The parameters for 2D DOSY 1H 
NMR experiments were as follows: LED pulse sequence with bipolar gradients, Δ=50 
ms diffusion time, δ=2.2 ms gradient duration; 2s repetition delay, and 16 averages. 
Diffusion was encoded using gradient pulses with a sinusoidal shape with 16 gradient 
steps ranging from 0.7 to 32 Gauss cm-1. All NMR data were processed using 
TOPSPIN software (Bruker). Samples were prepared by dissolving a mass of 
powdered tablets equivalent to 5 mg of analyte in 0.7 mL of deuterated DMSO, 
followed by sonication for 15 minutes, and centrifugation (3 min, 13,000 × g). The 
supernatant was poured into a 5-mm NMR tube for analysis. Individual standards of 
artemether, lumefantrine, mebendazole, and levamisole were prepared in DMSO 
providing final concentrations of 5 mg mL-1. 
Botanical Assays 
Pollen processing of eight tablets from suspect sample Ao-2012-2 and eight from 
authentic sample G-NOV-62 were identical in each case with weighing, crushing, hot 
water wash, acetolysis, hot 10% HCl, acetone wash, filtering through a 6 µm filter and 
mounting in unstained glycerine jelly on two slides under long coverslips (the total 
amount of residue remaining) (Newton et al. 2008). All slides were examined using 
an Axioplan 2 imaging microscope under a 10 × eyepiece, a ×1.25 Optovar and 
objectives at ×10, 20 and 100. Spores and pollen were identified under a total 
magnification of between 500 and 1000 times. Slides are stored in the palynological 
slide collection of GNS Science. A slide with glycerine jelly was exposed in the 
laboratory as a check for possible laboratory contamination by pollen (the laboratory 
has negative air pressure to prevent this happening). No pollen was found. 
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Packaging Analysis 
Packaging analysis was conducted on Ao-2012-1 and Ao-2012-2 using the hand 
held portable Counterfeit Detection Device #3 (CD-3) ( Ranieri et al. submitted) 
(Figures 1 & 2, Table 1). Analysis was performed in comparison to a genuine product 
and the differences in appearance and inner and outer packaging documented. The 
CD-3 device is used to screen pharmaceutical products using an alternate light source 
with multiple wavelengths in the visible (350 - 700 nm) and non-visible (>700 nm) 
electromagnetic spectrum. Images of the different inks (pigments/dyes) on the 
package and tablets of the falsified medicines versus the authentic products were 
captured in the CD-3 device. The genuine comparator for Ao-2012-1 was G-JJ-68: 
Vermox 500 mg, manufactured by Janssen-Cilag SpA, Latina Italy, batch number 
CIL8J00 and expiry date 09/2015; and for Ao-2012-2 was G-NOV-65: Coartem 
20/120, manufactured by Novartis Pharmaceuticals Corporation, New York, USA, 
batch number F2851 and expiry date 06/2014. Analysis conducted under UV-Vis and 
infrared light revealed significant differences between the suspect samples and the 
genuine comparators.   
 
Reporting 
We have used the distinction between falsified (or counterfeit or spurious medicines; 
i.e. ‘deliberately and fraudulently mislabeled with respect to identity and/or source’) 
and substandard medicines (i.e. ‘genuine medicines produced by manufacturers 
authorized….which do not meet quality specifications set for them by national 
standards’) (World Health Organization. 2008). To avoid any intellectual property 
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connotations the term falsified is used here instead of counterfeit (Newton et al. 2011, 
Attaran et al. 2012). 
 
The results are presented using the MEDQUARG guidelines (Newton et al. 2009), 
and were reported to the Angolan Inspecção Geral de Saúde, WHO Rapid Response 
(World Health Organization. 2013a,b,c), the manufacturers of the genuine products, 
United Nations Office on Drugs and Crime, the World Customs Organization and the 






Active Pharmaceutical Analysis 
 
No detectable levels of artemether or lumefantrine were observed by HPLC-DAD. 
MS and XRD methods described above were used to determine the chemical 
composition of the sample tablet Ao-2012-2. Figure 3 show the DART-MS analysis 
of a Coartem 20/120 sample, tablet # FE 24, manufactured by Novartis 
Pharmaceuticals Corporation, that contained the active ingredients artemether and 
lumefantrine, illustrating the theoretical m/z values, and isotopic pattern of 
artemether and lumefantrine response ion peaks for artemether and lumefantrine, 
and the DART-MS analysis of sample Ao-2012-2, zoomed into the mass spectral 
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region of the expected artemether and lumefantrine response peaks. Ionization of 
artemether by DART usually generates an ammonium adduct of the artemether 
molecule of type [M+NH4]+ with an exact mass of 316.2118 Da. The response peak 
for the genuine tablet was detected at m/z value of 316.2192 and the isotopic 
distribution matched with that theoretically expected. DART ionization of 
lumefantrine usually generates a protonated ion of type [M+H]+ with an exact mass 
of 528.1622 with a chlorine signature clearly evident in the isotopic distribution. 
The lumefantrine peak at m/z value of 528.1731 and the lumefantrine peak pattern 
as shown in Figure 3 were easily detected when the genuine tablet FE-24 was 
analysed. However, neither peak nor pattern was detected, even at various sample 
desorption temperatures (100-450 oC) when the sample tablet Ao-2012-2 was 
analysed. The experiment clearly demonstrated the absence of artemether and 
lumefantrine in the sample tablet Ao-2012-2. 
 
For further confirmation of the absence of the expected APIs in the sample Ao-
2012-2, the tablet was subjected to analysis by UHPLC-MS and UHPLC-TWIMS-
MS. A tablet solution, when analysed by the above methods, did not show any 




Positive and negative mode DART-MS and DART-MS/MS analysis of the suspect 
tablet Ao-2012-2 suggested the presence of polysaccharides as excipients in the 
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tablet. As demonstrated in Figure 4 positive mode analysis suggested the presence 
of a disaccharide in the sample. In the negative mode analysis of the sample, a 
series of peaks were detected, with a difference of 162.05 Da corresponding to a 
dehydrated hexose molecule (C6H12O6 – H2O) with the largest detected saccharide 
at m/z 925.2 corresponding to a pentasaccharide. This suggests that either a mixture 
of polysaccharides is present in the tablet or the polysaccharide is undergoing 
fragmentation between the ion source and the mass spectrometer inlet. Moreover, 
neutral loss of a phosphoric acid fragment when the tetrasaccharide and the 
pentasaccharide were subjected to collision induced dissociation (CID) suggests the 
presence of phosphates in the sample. Detection of only the disaccharide, in 
positive ion mode may be caused by fragmentation of the pentasaccharide prior to 
MS detection, possibly in the ionization region, to produce the disaccharide. 
Nonetheless, both positive and negative mode DART-MS and DART-MS/MS 
analysis suggest the presence of saccharides in the tablet. Furthermore, the mass 
peak at m/z 283.1794 seen in positive mode analyses was tentatively identified as 
the [(C2H4O)6+H2O+H]+ polyethylene glycol (PEG) ion and the fragmentation 
pattern (shown in Figure 4 B) suggests the presence of PEG and its fragments at 
m/z values of 267.1522, 239.1556, and 149.0249.  
 
Figure 5 indicates the XRD identification of one of the excipients present in the 
sample as brushite, a pale yellow mineral of chemical formula CaHPO4.2H2O. The 
sample produced the peaks shown in red and the blue lines represent the peaks 
expected for brushite based on that reported in the PDF database. Detection of 
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brushite can also explain the phosphoric acid loss in the polysaccharides DART-




UHPLC-MS sample analysis revealed the presence of pigment yellow 3, pigment 
yellow 81 and pigment yellow 151 in Ao-2012-2. Figures 6 A-C illustrate the 
extracted ion chromatograms for the [M-H]– ions at theoretical m/z 380.0995 for 
pigment yellow 151 (C18H15N5O5), m/z 393.0157 for pigment yellow 3 
(C16H12Cl2N4O4) and m/z 751.1161 for pigment yellow 81 (C36H32Cl4N6O4), which 
exhibited retention times of 4.18 min, 6.99 min and 8.10 min, respectively. For 
each pigment, elemental formulae were generated based on the expected mass 
accuracy and experimental isotopic pattern. Mass spectra for each target 
compounds are displayed in Figure 6 D-F, with monoisotopic peaks at m/z 
380.1034 (Δm=3.9 mDa) for pigment yellow 151, m/z 393.0125 (Δm=3.2 mDa) for 
pigment 3, and m/z 751.1196 Da (Δm=3.5 mDa) for pigment 81, confirming the 
identity of these compounds. 
 
Botanical Assays 
The authentic sample G-NOV-62 contained fine cellular and amorphous organic 
material, including plant fragments, black chips and rounded crystals of starch. A 
relatively large number of fungal spores with very rare pollen, including Pinus, 
Poaceae and Casuarina were found. A common fungal spore had a thick dark cell 
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wall, 3-4 pores and diameter 20-50 µm. Tablets from Ao-2012-2 contained some 
Pinus and Coprosma pollen. Further analysis of photographs of the fungal spores 
suggests that sample Ao-2012-2 contains Epicoccum nigrum spores. This is a 
fungus associated with dead herbaceous stems and grasses but is of global 
distribution. The pollen and spore analysis therefore did not give any firm clues as 
to the origin of the raw ingredients or place of manufacture of Ao-2012-2. However, 
brushite is associated with environments with only sparse vegetation present and is 
relatively common in India and is also used extensively in Chinese herbal 




The packaging of Ao-2012-2 differed from that of a genuine sample (Table 1 A, 
Figure 1), strongly suggesting that the sample was falsified, consistent with chemical 
analysis conclusions. The details of all errors are not disclosed in this report to avoid 
assistance to criminals. The stapling of the sample card, incorrect manufacture and 
expiry date interval stamps, much thinner card and lower card weight, the use of ‘-‘ in 
‘Anti-malarial agent’ differ from those on the genuine. In addition, the tablets of Ao-
2012-2 were pitted, in contrast to the smooth surface of the genuine tablets.  When 
examined and compared against the front of the blister with CD-3 using UV-Visible 
light, Ao-2012-2 had a brighter red colour for the dosage text, a greener blister colour 
and a lighter AMFm logo colour. Also under UV-Visible light, the background colour 
of the reverse of the blister was yellow for the genuine sample but greener for Ao-
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2012-2. The colour of the falsified tablets was greener than the tablets from the 




Active Pharmaceutical Ingredient Analysis 
 
DART-MS and DART-MS/MS analysis of the levamisole standard and the suspect 
tablet are shown in Figure 9 B-E. Two major response ions at m/z values of 
409.1484 and 205.0849 were observed when sample Ao-2012-1 was analysed by 
DART-MS in positive ion mode. Due to low relative intensity of the peak at m/z 
409.1484 with respect to the peak at m/z 205.0849, only the latter is displayed in 
the figure. The tablet was supposed to contain mebendazole as the API, and should 
have produced a protonated ion peak at m/z 296.1029. When the standard of 
mebendazole was analysed, a protonated ion of mebendazole of type [M+H]+ at m/z 
296.1124 was detected, where M represents the neutral molecule. Peaks at m/z 
values corresponding to different adduct, fragments, and clusters of mebendazole 
were also searched for, but not found in the mass spectrum of sample Ao-2012-1. 
Identification of the chemical present in the suspect tablet in place of mebendazole 
was then carried out. Collision induced dissociation (CID) of the ion at m/z 
409.1484 generated a product ion at m/z 205.0842; CID of the ion at m/z 205.08 
produced a major product ion at m/z 178.0729 (Figure 9 C). From these results it 
was tentatively inferred that the ion at m/z 409.1484 was a dimer ion, [2M+H]+, of 
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an analyte that produced a monomer at m/z 205.0849. Search within the NIST 
(National Institute of Standards and Technology) database for a protonated 
monomer [M+H]+ ion with m/z 205 that produces a product ion at m/z 178 
suggested the tentative identity of the response peak to be levamisole (Figure 9 A). 
The exact mass of the [M+H]+ ion of levamisole is 205.0799 Da. For confirmation 
of the tentatively identified compound, a levamisole standard was purchased and 
subjected to DART-MS and DART-MS/MS analysis. Analysis of the levamisole 
standard produced a response ion peak at m/z value of 205.0862 which when 
subjected to CID generated a major product ion at m/z 178.0729 tentatively 
identified as [M–HCN+H]+. The experiment thus suggested that the suspect tablet 
does not contain mebendazole, but it contains levamisole instead.  
 
To further confirm the identity of the chemical present in the tablet, the sample 
tablet and the mebendazole and levamisole standards were analysed by UHPLC-
MS and UHPLC-TWIMS-MS. Figure 10 shows the results of the UHPLC-MS 
analysis of the tablet and the standards. Chromatographic retention time for the 
mebendazole standard was 2.04 minutes. The extracted mass spectrum from this 
chromatographic peak showed signals corresponding to the protonated ion and the 
fragment ion of mebendazole at m/z 296.1014 and m/z 264.0757, respectively. The 
sample tablet did not show any chromatographic peak at ~2 minutes, however, a 
doublet peak in the retention time range of 1.1-1.37 minutes was detected. The 
mass spectrum extracted from the doublet chromatographic peak showed the 
presence of signals at m/z 205.0771 and m/z 178.0708. Subsequent analysis of a 
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levamisole standard also produced a chromatographic doublet peak in the retention 
time range of 1.1 -1.37 minutes, similar in shape to that observed for Ao-2012-1. 
The extracted mass spectrum from this chromatographic peak showed the presence 
of signals at m/z 205.0771 and m/z 178.0708 corresponding to the protonated 
precursor and product ions of levamisole as discussed earlier. To add to the 
identification confidence, ion mobility separation (IMS) (Kanu et al. 2008, 
Eiceman & Karpass 1993) that separates ions based on their size-to-charge ratio 
(Ω/z) instead of the mass-to-charge ratio (m/z) was also performed. Ions of same 
m/z can be separated by IMS if they have different size-to-charge ratios, such as in 
the case of isobars that are impossible to separate by MS alone. Under identical 
experimental and instrumental conditions, the parameter termed as “drift time” is 
specific for a chemical and is used as a chemical characterization parameter. Figure 
11 shows results of the UHPLC-TWIMS-MS analysis. Both the suspect sample and 
the levamisole standard produced peaks at m/z 205.0771 and m/z 178.0708, 
respectively; with a retention time of 1.1-1.37 min and a drift time of 2.48 ms. The 
mobility peak also was a doublet peak supporting the inference that structural 
isomers of levamisole are present in the sample as well as in the standard.  These 
experiments thus confirmed the absence of mebendazole in the tablet and the 
unexpected presence of levamisole. 
 
Quantitation of levamisole in Ao-2012-1 
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For quantitation of levamisole, a 6.57 mM stock solution and standards ranging 
between 4.4 µM and 440 µM were prepared. Standard solutions and that of the 
sample tablet were analysed by UHPLC-MS/MS in duplicate. A calibration curve 
was established using the levamisole chromatographic peak area then used to 
calculate the concentration of levamisole present in the tablet (Figure 12). Based on 
the weight of tablet and the dilution factors used, the sample Ao-2012-1 contained 
0.36 grams of levamisole per gram of tablet weight. With a tablet weight of ~750 
mg this yields 270 mg levamisole/tablet. 
 
Excipient MS analysis 
 
Negative mode DART-MS analysis of the suspect tablet suggested the presence of 
a disaccharide (such as lactose) in the tablet. As illustrated in Figure 13 A-B, ions at 
m/z values of 359.0739, 323.0956, 283.2637, 255.2328 and 150.0565 were detected. 
The ion at m/z 359.0739 was tentatively assigned to a disaccharide (exact mass 
342.1157 Da) observed as the deprotonated water adduct, [M+H2O–H]–. Negative 
ions formed after the neutral loss of two water molecules from this adduct result in 
the peak at m/z 323.0956. Further fragmentation of the disaccharide generates the 
product ion of type [M–C5H8O5–H2O–H]– at m/z 194.0442. Fragmentation and 
isotopic distribution patterns of the ion at m/z 359.07 supported the tentative 
identification of this excipient as a disaccharide, such as lactose.  Furthermore, the 
signal at m/z 283.2637 was tentatively identified as stearic acid, forming an ion of 
type [M – H]– with an exact mass of 283.2631. The product ion detected at m/z 
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255.2328 was assigned to an ion of type [M–C2H4–H]– generated with the loss of 




Figure 13 C demonstrates the XRD identification of one of the excipients present in 
the sample as calcite (CaCO3). The sample produced the peaks shown in red and 
the blue lines represent the diffraction pattern expected for calcite based on that 




Errors in language on the packet and the leaflet strongly suggested that the sample 
was falsified, corroborating chemical analysis results (Table 1 B, Figure 2). Language 
errors were common, suggesting that the forger may have had some knowledge of 
English but little of French and Spanish. The details of all errors are not disclosed in 
this report to avoid assistance to criminals. The batch numbers on the blister and 
packet were invalid. However, the packet was stamped with a valid Nigerian National 
Medicines Regulatory Agency (NAFDAC) registration number. Interestingly, the 
genuine leaflet had one English error in the pregnancy and lactation section 
‘Mebendazolehas….’, that was also found on the leaflet of the falsified sample. 
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UV-Visible and infrared images of the falsified and genuine packaging readily 
demonstrated significant differences between them. On the suspect sample outer 
packaging the dosage information text had a brighter red colour relative to that 
observed for the genuine sample. The shaded area on the front of the outer packet of 
the genuine product was darker in colour than that observed on the suspect sample 
packet. In addition, differences in the texture and printing of the packet as well as in 
the stamped expiry date and batch information between the suspect and the genuine 
samples were evident (Figure 14). Unlike that observed for the genuine sample, the 
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Table 1A. Distinguishing features of falsified artemether-lumefantrine labelled as made by 
Novartis. Details of some errors have been omitted to avoid assisting those producing the 
falsified product. These details may be requested from the corresponding author. 
Variable Genuine Falsified 
 G-NOV-65 Ao-2012-2 
Packet 
Stated manufacturer ‘Manufactured by: 
Novartis Pharmaceuticals 
Corporation, Suffern, New York, 
USA for Novartis Pharma AG, Basle, 





Corporation, Suffern, New York, 
USA for Novartis Pharma AG, 
Basle, Switzerland, under licence 
from the PRC 
5002835’ 
No. tablets 24 24 
Tablet text CG 
N  | C 
CG 
N | C 
Tablet appearance Surface pitted without clear ‘lines’ Surface smooth with clear ‘lines’ 
Tablet diameter/thickness/mm 9.10/3.10 * 9.50/3.50 
Tablet colour RBG % above ‘C’ R 130 G 127 B 40 R 125 G 125 B 46 
Folded blister enclosure Folded and glued Folded and stapled 
Logos ACTm 
Mosquito and shadow 
ACTm 
Mosquito and shadow 
Batch: F2851 F2261 
Mfd: 07 2012 01 2012 
Exp: 06 2014 01 2014 
 Difference between Mfd and Exp of 
23 months 
Difference between Mfd and Exp of 
24 months 
Packet card thickness 0.45 mm 0.25 mm 
Packet length and width 11.8 cm x 14.9 cm 11.8 cm x 14.9 cm 
Packet weight (without blister & 
tablets)/g 
8.48  5.94  
Text differences Anti malarial agent Anti-malarial agent 
Blister 
Text Coartem ® 
(artemether/lumefantrine) 




20 mg/ 120 mg Tablets 
logo NOVARTIS 
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Weight and thickness specification ranges for Coartem are 0.228-0.252 g and 3.0-3.4 mm,  













Embossed F 2851    06 2014 1- 1901   01 2014 
Tablet chemical analysis   
DART MS, ESI-MS, UHPLC-
MS and ESI-UHPLC-TWIMS-
MS 
Artemether and lumefantrine detected Artemether and lumefantrine not 
detected 
DART-MS, DART-MS/MS Artemether and lumefantrine detected Polysaccharides and polyethylene 
glycol 
HPLC-UV Artemether and lumefantrine detected Artemether and lumefantrine not 
detected 
XRD N/A Brushite, CaHPO4.2H2O 
Raman Signature very similar to genuine Signature very different from that 
of genuine 
NMR Artemether and lumefantrine 
detected. 
 
Artemether and lumefantrine not 
detected. 
Signature very different from that 
of genuine 
Tablet pollen and spore 
analysis 
G-NOV-62 Ao-2012-2 
Acetolysis Solution turned black after 5 minutes 
indicating the presence of corn starch 
Solution turned yellow after 5 
minutes and remained yellow 
throughout processing 
 Fine cellular and amorphous organic 
material, including plant fragments 
and black chips. Rounded crystals of 
starch present. A relatively large 
number of fungal spores with very 
rare pollen, including Pinus, Poaceae 
and Casuarina. A common fungal 
spore had a thick dark cell wall and 
3-4 pores and diameter 20-50 µm. 
The fungal spores were identified 
from photographs as Alternaria sp. 
and Monodictys sp. 
Pinus, Coprosma pollen and 
Epicoccum nigrum spores 
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Table 1B. Features of falsified mebendazole labelled as ‘Vermox® 500mg’ made by 
‘Janssen-Cilag’. Details of some errors removed to avoid assisting those producing the 
falsified product. These details may be requested from the corresponding author. 
Variable Genuine Falsified 
Packet G-JJ-68 Ao-2012-1 
Stated manufacturer ‘JANSSEN-CILAG’ ‘JANSSEN-CILAG’ 
 ‘Manufactured by: JANSSEN-
CILAG SpA. – V.C. JANSSEN -
 Borgo S. Michele – 04010 Latina – 
Italy for Janssen Pharmaceutica N.V., 
Turnhoutseweg 30, B-2340 Beerse, 
Belgium’ 
‘Manufactured by: JANSSEN-CILAG 
SpA. – V.C. JANSSEN - Borgo S. 
Michele – 04010 Latina – Italy for 
Janssen Pharmaceutica N.V., 
Turnhoutseweg 30, B-2340 Beerse, 
Belgium’ 
Other text mebendazol 500 mg para un 
comprimido 
 
1 tableta oral 
mebendazol 500 mg para un 
comprimido 
 
1 tableta oral 
Colour of inside surface of 
packet 
Creamy white Matt white 
Text language French, English, Spanish French, English, Spanish 
Batch no : CIL8J00 9CL2400 
Mfg. date : 10-2012 09-2011 
Expiry : 09-2015 08-2014 
Other Codes NAFDAC REG. No. 04-1682 NAFDAC REG. No. 04-1682 
 NG 963564 116 NG 963564 116 
Bar Codes Two bar codes on two side tabs Two bar codes on two side tabs 
Blister   
No. of tablets 1 1 
Tablet colour  White White 
Tablet weight/mg  ~750  
BN CIL8J00 AII 0800 
Mfg/Exp: 10-2012/09-2015 09-2010 / 08-2013 
BN and   Mfg/Exp:  embossed Embossed 
Logo  Stylised ‘horse’ logo design on blister 
and packet not the same 
Leaflet   
Leaflet weight/g 5.94 6.51 
Tablet chemistry   
DART MS, UHPLC-MS Mebendazole  No mebendazole detected. Levamisole 






































and UHPLC-TWIMS-MS detected 
ESI-UHPLC-MS Mebendazole Levamisole concentration = 0.36 grams 
of levamisole /gram of tablet weight. 
With a tablet weight of ~ 750mg this 
gives 270 mg levamisole /tablet 
 
Excipient DART-MS N/A carbohydrates & stearic acid 
Excipient X-ray powder 
diffraction (XRD) 
N/A calcite 
Calcite IRMS N/A hydrothermal or medical in origin 
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Figures 
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Figure 3. Positive mode DART-MS spectra of a genuine Coartem 20/120 (sample # FE-24) manufactured by Novartis 
pharmaceuticals showing the detection of A) artemether as its [M + NH4]+ ion; B) theoretical m/z value and isotopic distribution of 
artemether;  C) lumefantrine as its [M + H]+ ion; D) theoretical m/z values and isotopic distribution of lumefantrine; E) full mass 
spectrum of genuine sample (FE-24) in the m/z range of 290-550 showing the presence of both artemether and lumefantrine peaks; and 
F) full mass spectrum of sample # Ao-2012-2 in the m/z range of 290-550 showing the absence of artemether and lumefantrine signals. 
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Figure 4: DART-MS and MS/MS analysis of sample tablet Ao-2012-2 in positive mode (left panels) and negative mode (right panels). 
A: Full mass spectrum, B: MS/MS spectrum of m/z 283.1794 (polyethylene glycol), and C: MS/MS spectrum of m/z 342.1454 
(disaccharide), D: Full mass spectrum, and E: MS/MS spectrum of m/z 763.1701 (pentasaccharide). Loss of 97.97 suggests the 




Figure 4: DART-MS and MS/MS analysis of sample tablet Ao-2012-2 in positive mode (left panels) and negative mode (right panels). 
A: Full mass spectrum, B: MS/MS spectrum of m/z 283.1794 (polyethylene glycol), and C: MS/MS spectrum of m/z 342.1454 
(disaccharide), D: Full mass spectrum, and E: MS/MS spectrum of m/z 763.1701 (pentasaccharide). Loss of 97.97 suggests the 
presence of phosphoric acid as an adduct with the pentasaccharide. 
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Figure 5: XRD scan of the of the sample tablet Ao-2012-2. XRD scan shows the sample 
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Figure 6. UHPLC-MS pigment analysis of Ao-2012-2. Extracted ion chromatogram for pigment 
151 with m/z 380.0995 ± 0.0050 (A), pigment 3 with m/z 393.0157 ± 0.0050 (B), and pigment 81 
with m/z 751.1161 ± 0.0050 (C). Mass spectra extracted from chromatographic peaks in the 
retention time range of 3.50-5.00 min for pigment 151 (D), 6.50-7.50 min for pigment 3 (E), and 
8.00-8.50 min for pigment 81 (F).  
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Figure 7. Images captured by the CD-3. Genuine AMFm Coartem (top), falsified Coartem (Ao-
2012-2) (bottom) under UV-Visible light demonstrating different background colours and red for 
‘20/120’. 
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Figure 8. Images captured by the CD-3. Falsified AMFm Coartem (Ao-2012-2) (left), and 
genuine AMFm Coartem (right) demonstrating different tablet colours. 
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Figure 9. DART-MS and DART-MS/MS analysis of levamisole standard and suspect tablet. A) 
Fragmentation pattern of levamisole reported in the National Institute of Standards and 
Technology (NIST) database; B) Full mass spectrum of the levamisole standard with [M+H]+ at 
m/z 205.0862 (Δm=6.3 mDa); C) Product ion mass spectrum for the [M+H]+ precursor ion of 
levamisole at m/z 205.0856 (Δm=5.7 mDa) with a collision energy of 15 eV; D) Full mass 
spectrum of the suspect tablet Ao-2012-1; and E) Product ion mass spectrum for the [M+H]+ 
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Figure 10: UHPLC-MS analysis of suspect tablet and standards of mebendazole and levamisole 
(Y-axis: intensity for all panels; X-axis (retention time in minutes for panels A, B, C, D, and E 
and m/z for panels A1, B1, C1, D1, and E1. Total ion chromatograms obtained of A: mebendazole; 
B and C: levamisole standard at two different concentrations; and D and E: suspect tablet at two 
different concentrations. Mass spectra extracted from chromatographic peaks in the retention 
time range of 1.9-2.25 min for A1 and 1.11-1.35 min for B1, C1, D1, and E1. Theoretical masses 
of the [M + H]+ ions of mebendazole (C16H13N3O3) and levamizole (C11H12N2S) are 296.1029 
and 205.0799, respectively. Experimental m/z values measured for the standards of mebendazole 
and levamisole were 296.1014 and 205.0793, respectively. 
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Figure 11: UHPLC-TWIMS-MS analysis of standard levamisole (left panel) and suspect tablet 
(right panel).  Y-axis: Signal Intensity for all panels; X-axis: Retention time in minutes for panels 
A, B, A1 and B1, and Drift time in milliseconds for panels C and C1. A and A1: extracted ion 
chromatogram at m/z 205.0771 ± 0.0050 corresponding to [M + H]+ ion of levamisole, B and B1: 
total ion chromatogram,  C and C1: extracted ion mobility chronogram for the [M + H]+ ion of 
levamisole at m/z 205.0771 ± 0.0050.  	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Figure 12: Calibration curve for the quantitation of levamisole present in the sample Ao-2012-1. 
Concentrations of the levamisole standards are shown next to the data points. To introduce a self 
check in the calibration curve a levamisole standard solution of 44 mM concentration was 
prepared from a stock solution different from the one used to prepare the dilutions along the 
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Figure 13: Negative mode DART-MS analysis (left panel) and XRD scan (right panel) of the of the sample tablet Ao-2012-1. A) full 
DART-MS spectrum of the sample, B) MS/MS spectrum of the precursor ion at m/z 359.0762, and C) XRD scan showing that the 
sample diffraction pattern (red) matches with calcite diffraction pattern (blue). 
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Figure 14. Images captured by the CD-3. Falsified mebendazole (Ao-2012-1) (left), genuine 
mebendazole (right), demonstrating different colours, under UV-Visible light for the central line 
on the box packaging. 
 
 
 
 
 
 	  
